The packet does not identify specific disease-causing genes; the known_genes field is empty. An autosomal dominant inheritance pattern is listed in the packet; however, no supporting gene is documented, limiting characterization of any hereditary contribution. The OMIM entry (155720) is the primary sourcing reference for the genetic dimension.

Per the OMIM and Orphanet-sourced definition, diagnostic procedures include ophthalmoscopic examination, fluorescein angiography, and ultrasound. Cell type classification distinguishes epithelioid, intermediate, mixed cell, and spindle cell types (spindle type further subclassified as A and B). Additional diagnostic criteria are not detailed in this packet.

Two FDA-approved therapies are identified in the packet's approved_treatments field: melphalan hydrochloride (HEPZATO KIT), approved by FDA/CDER in August 2023; and tebentafusp (KIMMTRAK), approved by FDA/CDER in January 2022; both with active market status. The disease definition also references surgical excision, iridocyclectomy, tumor resection, radiotherapy, and photocoagulation as described treatment modalities.

A dedicated natural history or prognosis field is not present in this packet. Uveal melanoma is the most common primary intraocular tumor in Western populations per the disease definition. Prognosis information beyond this context is not certified in this packet.

Active clinical research is reflected in the packet's trial records. Among listed studies: NCT07804186 (Phase 3) evaluates adjuvant darovasertib and crizotinib for primary non-metastatic uveal melanoma, sponsored by IDEAYA Biosciences; NCT07057596 (Phase 2) studies neoadjuvant tebentafusp in metastatic uveal melanoma; NCT06070012 (Phase 2) examines tebentafusp in HLA-A*0201-positive previously untreated metastatic disease. Additional trials are registered on ClinicalTrials.gov.